Apixaban (eliquis) for stroke prevention in atrial fibrillation.

Apixaban is at least as effective as aspirin or warfarin for preventing strokes in high-risk patients with nonvalvular atrial fibrillation, especially those who cannot or will not take warfarin. It is slightly less likely to cause major bleeding and may have better compliance because it does not require frequent laboratory monitoring. However, apixaban is significantly more expensive than warfarin or aspirin, and its anticoagulation effect cannot be reversed in the event of an emergency.